Showing 1,061 - 1,080 results of 225,503 for search '(( 10 ((nm decrease) OR (a decrease)) ) OR ( 50 ((we decrease) OR (mean decrease)) ))', query time: 1.67s Refine Results
  1. 1061
  2. 1062
  3. 1063

    Four-fold decrease in [H<sup>+</sup>]<sub>e</sub> shifted GLT-1a E<sub>rev</sub> by −18 mV at both low and high glutamate concentrations. by Anatoli Y. Kabakov (729047)

    Published 2015
    “…<b>(C)</b> Average GLT-1 E<sub>rev</sub> shifts at 37.5 μM and 600 μM are approximately equal when [H<sup>+</sup>]<sub>e</sub> was decreased from 40 to 10 nM.</p>…”
  4. 1064

    CPGF NPs decrease the growth kinetics of breast cancer cells. by Kirtee D. Wani (636463)

    Published 2014
    “…<p>(<b>A</b>) The NPs decreased the number of cells in MDAMB231 and MCF7, indicated by cell growth assay. …”
  5. 1065
  6. 1066
  7. 1067

    ATM/ATR substrates with synergistic increase and decrease in phosphorylation by FGF21/insulin co-treatment. by Darwin V. Lee (653885)

    Published 2014
    “…<p>Legend: * - phosphorylation, # - oxidized methionine, § - published site hASC-adipocytes were treated with FGF21 (10 nM) either alone or in combination with insulin (10 nM) for 30 min prior to harvest. a) Lysates were subject to western blot for pAkt and pERK. b) Densitometric quantification of western blots.…”
  8. 1068

    GSH, but not GSSG, specifically decreases ABCB10 ATP binding activity. by Wei Qiu (217045)

    Published 2015
    “…<p>A representative autoradiography image and the quantification shown in the bar graph demonstrate that GSH decreased [α-<sup>32</sup>P] 8-azido-ATP signal in ABCB10 from SMPs in a dose dependent manner, whereas GSSG did not. …”
  9. 1069
  10. 1070
  11. 1071
  12. 1072
  13. 1073
  14. 1074

    Decrease of NF-κB activity in tumor tissue of CCR5<sup>−/−</sup> mice. by Ju Kyoung Song (324058)

    Published 2013
    “…<p><b>A</b>, The DNA binding activity of NF-κB was determined in the nuclear extracts of the CCR5<sup>−/−</sup> mice and CCR5<sup>+/+</sup> mice tumor tissues by EMSA described in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0033747#s4" target="_blank">material and methods</a>. …”
  15. 1075

    AZP-531, an unacylated ghrelin analog, improves food-related behavior in patients with Prader-Willi syndrome: A randomized placebo-controlled trial by Soraya Allas (4752756)

    Published 2018
    “…AZP-531, a first-in-class UAG analog, was shown to inhibit the orexigenic effect of AG in animals, to improve glycemic control and decrease body weight in humans. We aimed to investigate the safety and efficacy of AZP-531 in patients with PWS for whom no approved treatment for hyperphagia is currently available.…”
  16. 1076
  17. 1077
  18. 1078
  19. 1079
  20. 1080